个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Tracking of Multimodal Therapeutic Nanocomplexes Targeting Breast Cancer in Vivo

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ 自然指数

作者：
Bardhan, Rizia[2] * ; Chen, Wenxue[3] * ; Bartels, Marc[1] ; Perez-Torres, Carlos[4] ; Botero, Maria F.[5] ; McAninch, Robin Ward[5] ; Contreras, Alejandro[5] ; Schiff, Rachel[5] ; Pautler, Robia G.[4] ; Halas, Naomi J.[2,6] ; Joshi, Amit[1] ;
机构： [1]Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA [2]Rice Univ, Dept Chem, Houston, TX 77005 USA [3]Hebei Med Univ, Hosp 4, Dept Obstet & Gynecol, Hebei Prov Tumor Hosp, Shijiazhuang 050011, Hebei Province, Peoples R China [4]Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA [5]Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA [6]Rice Univ, Dept Elect & Comp Engn, Houston, TX 77005 USA
出处：
DOI： 10.1021/nl102889y
ISSN：

关键词： Multimodal imaging in vivo nanoshells fluorescence optical imaging magnetic resonance imaging biodistribution

摘要：
Nanoparticle based therapeutics with local delivery and external electromagnetic field modulation holds extraordinary promise for soft tissue cancers such as breast cancer however knowledge of the distribution and fate of nanoparticles in vivo is crucial for clinical translation Here we demonstrate that multiple diagnostic capabilities can be Introduced in photothermal therapeutic nanocomplexes by simultaneously enhancing both near Infrared fluorescence and magnetic resonance imaging (MRI) We track nanocomplexes in vivo, examining the influence of HER2 antibody targeting on nanocomplex distribution over 72 h This approach provides valuable detailed information regarding the distribution and Fate of complex nanoparticles designed for specific diagnostic and therapeutic functions

基金：
Baylor College of Medicine Faculty Seed [2680150801]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R42 CA115028-02, R01 CA151962-01, P30DK079638]; DoDUnited States Department of Defense; NSSEFF; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9550 06-1-0021]; Robert A Welch FoundationThe Welch Foundation [C-1220]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50 CA058183]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, R42CA115028, P50CA058183, P50CA058183, P50CA058183, R01CA151962, R01CA151962, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, R01CA151962, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, R01CA151962, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, R01CA151962, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, R01CA151962, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, R42CA115028, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, R42CA115028, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183, P50CA058183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK079638, P30DK079638, P30DK079638, P30DK079638, P30DK079638, P30DK079638] Funding Source: NIH RePORTER

基金编号： 2680150801 R42 CA115028-02 R01 CA151962-01 P30DK079638 FA9550 06-1-0021 C-1220 P50 CA058183 P50CA058183 R42CA115028 R01CA151962 P30DK079638

语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2010]版：
大类 | 1 区 工程技术
小类 | 1 区 化学综合 1 区 材料科学：综合 1 区 纳米科技
最新[2025]版：
大类 | 2 区 材料科学
小类 | 1 区 化学：综合 1 区 物理：应用 1 区 物理：凝聚态物理 2 区 材料科学：综合 2 区 纳米科技
JCR分区：
出版当年[2010]版：
Q1 CHEMISTRY, PHYSICAL Q1 NANOSCIENCE & NANOTECHNOLOGY Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY Q1 CHEMISTRY, MULTIDISCIPLINARY Q1 PHYSICS, CONDENSED MATTER Q1 PHYSICS, APPLIED
最新[2023]版：
Q1 CHEMISTRY, MULTIDISCIPLINARY Q1 CHEMISTRY, PHYSICAL Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY Q1 NANOSCIENCE & NANOTECHNOLOGY Q1 PHYSICS, APPLIED Q1 PHYSICS, CONDENSED MATTER

影响因子： 最新[2023版] 最新五年平均 出版当年[2010版] 出版当年五年平均 出版前一年[2009版] 出版后一年[2011版]

第一作者：
第一作者机构： [2]Rice Univ, Dept Chem, Houston, TX 77005 USA
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Bardhan Rizia,Chen Wenxue,Bartels Marc,et al.Tracking of Multimodal Therapeutic Nanocomplexes Targeting Breast Cancer in Vivo[J].NANO LETTERS.2010,10(12):4920-4928.doi:10.1021/nl102889y.
APA：
Bardhan, Rizia,Chen, Wenxue,Bartels, Marc,Perez-Torres, Carlos,Botero, Maria F....&Joshi, Amit.(2010).Tracking of Multimodal Therapeutic Nanocomplexes Targeting Breast Cancer in Vivo.NANO LETTERS,10,(12)
MLA：
Bardhan, Rizia,et al."Tracking of Multimodal Therapeutic Nanocomplexes Targeting Breast Cancer in Vivo".NANO LETTERS 10..12(2010):4920-4928

相关文献

[1]Targeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells [2]VEP-M在视觉通路病变中的应用价值(附18例报道) [3]智能化舌体(形)测算仪的研制及应用-附1733例患者检测初步分析 [4]阿帕替尼治疗腹腔低度恶性肌纤维母细胞肉瘤1例及文献回顾 [5]肺结节中西医结合全程管理专家共识 [6]早发型胃癌的特点及研究进展 [7]micrornas在口腔扁平苔藓组织中的表达谱分析及3种mirna的血清学表达 [8]基于cesm影像与病理指标预测乳腺癌her-2和ki-67表达的价值 [9]grhl2与雌激素相关性肿瘤发展关系的研究进展 [10]pd-l1与肿瘤相关免疫细胞的表达在口腔鳞状细胞癌发生发展中的作用

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号